Holen Sie sich die Stockscreener-App
34.47
3.05%
0.99
Schlusskurs vom Vortag:
$33.48
Offen:
$33.82
24-Stunden-Volumen:
866.33K
Relative Volume:
0.40
Marktkapitalisierung:
$3.54B
Einnahmen:
$164.01M
Nettoeinkommen (Verlust:
$-65.04M
KGV:
-50.17
EPS:
-0.687
Netto-Cashflow:
$-383.84M
1W Leistung:
+1.68%
1M Leistung:
+19.13%
6M Leistung:
+27.12%
1J Leistung:
+73.54%
1-Tages-Spanne:
$33.77
$35.74
1-Wochen-Bereich:
$32.84
$36.75
52-Wochen-Spanne:
$15.60
$36.88
Beam Therapeutics Inc Stock (BEAM) Company Profile
Firmenname
Beam Therapeutics Inc
Sektor
Branche
Telefon
857-327-8775
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
34.44 | 3.53B | 164.01M | -65.04M | -383.84M | -0.687 |
VRTX
Vertex Pharmaceuticals Inc
|
520.68 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
646.22 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
944.59 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
315.56 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.44 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-10-09 | Eingeleitet | Jefferies | Buy |
| 2025-03-28 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-03-10 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-08 | Herabstufung | Jefferies | Buy → Hold |
| 2023-10-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Eingeleitet | Citigroup | Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-01-05 | Eingeleitet | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-24 | Fortgesetzt | Stifel | Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Redburn | Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-08-05 | Eingeleitet | William Blair | Outperform |
| 2020-03-02 | Eingeleitet | Barclays | Overweight |
| 2020-03-02 | Eingeleitet | JP Morgan | Overweight |
| 2020-03-02 | Eingeleitet | Jefferies | Buy |
| 2020-03-02 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten
Beam Therapeutics (BEAM) CEO exercises options and sells 50K shares under plan - Stock Titan
BEAMBeam Therapeutics Inc Latest SEC Filings - Finviz
Hedge Fund and Insider Trading News: Paul Singer, Warren Buffett, Ray Dalio, George Soros, Millennium Management, Point72 Asset Management, Citadel Investment Group, CG Oncology Inc (CGON), Beam Therapeutics Inc (BEAM), and More - Insider Monkey
BEAM News | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Beam Therapeutics(BEAM.US) 10% Shareholder Sells US$10.04 Million in Common Stock - Moomoo
Form 144 BEAM THERAPEUTICS INC. For: 29 June By Investing.com - Investing.com South Africa
FMR LLC sells $10.04 million in Beam Therapeutics shares By Investing.com - Investing.com Australia
BEAM (NASDAQ: BEAM) insider files to sell 25,000 shares via option exercise - Stock Titan
Form 4 Beam Therapeutics Inc For: 29 June By Investing.com - Investing.com Nigeria
FMR LLC sells $10.04 million in Beam Therapeutics shares - Investing.com
FMR LLC (BEAM) trims Beam Therapeutics stake with 284,860-share open-market sale - Stock Titan
Beam Therapeutics Inc.(NasdaqGS: BEAM) added to Russell 2000 Value Benchmark - marketscreener.com
Beam Therapeutics Inc.(NasdaqGS: BEAM) added to Russell 3000E Value Benchmark - marketscreener.com
BEAM Stock's Gains Fade Despite Promising Data Rare Liver Disease Treatment Data - Stocktwits
Beam Therapeutics: A Better Entry Point Is Likely Coming (Rating Downgrade) (NASDAQ:BEAM) - Seeking Alpha
Beam Therapeutics, Inc. Actuals & Estimates (NASDAQ:BEAM) - TradingView
Top Beam Therapeutics (BEAM) Competitors 2026 - MarketBeat
BEAM Forecast — Price Target — Prediction for 2027 - TradingView
Beam Therapeutics, Inc. Actuals & Estimates (BMV:BEAM) - TradingView
Price to sales forward of Beam Therapeutics Inc. – NASDAQ:BEAM - TradingView
Enterprise value to EBIT forward of Beam Therapeutics Inc. – NASDAQ:BEAM - TradingView
Enterprise value to EBITDA forward of Beam Therapeutics Inc. – NASDAQ:BEAM - TradingView
Beam Therapeutics (BEAM) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
The Technical Signals Behind (BEAM) That Institutions Follow - Stock Traders Daily
Wedbush Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Beam Therapeutics stock soars 21% in three months: Here's why - MSN
Beam Therapeutics president exercises 35,505 options | BEAM Insider Trading - Stock Titan
Beam Therapeutics stock hits 52-week high at 36.66 USD By Investing.com - Investing.com Australia
Beam Therapeutics stock hits 52-week high at 36.66 USD - Investing.com
Clinical: Beam Advances Base Editing For PKU - CRISPR Medicine News
Beam Therapeutics Inc (BEAM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria - The Globe and Mail
Beam Therapeutics (BEAM) Receives FDA Approval for BEAM-304 IND Application - GuruFocus
Beam gets FDA clearance for BEAM-304 PKU gene-editing trial - Stock Titan
Beam Therapeutics gets FDA clearance for BEAM-304 - grafa.com
Beam Therapeutics gets FDA clearance for PKU gene therapy trial - Investing.com
Beam Therapeutics gets FDA clearance for PKU gene therapy trial By Investing.com - Investing.com South Africa
Beam Therapeutics Inc (BEAM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Beam Therapeutics Announces Clearance of Investigational - GlobeNewswire
Beam Therapeutics Inc (BEAM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Beam Therapeutics Inc (BEAM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Beam Therapeutics Inc (BEAM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Beam Therapeutics Inc (BEAM) Institutional Confidence - TradingKey
BEAM Stock Price, Quote & Chart - ChartMill
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why - The Globe and Mail
Is Beam Therapeutics Inc. (BEAM) One of the Best Genomics Stocks to Buy According to Analysts? - Insider Monkey
Finanzdaten der Beam Therapeutics Inc-Aktie (BEAM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):